MedTrace Logo

Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease

NCT02542319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2022-09-06

No results posted yet for this study

Summary

Randomized placebo-controlled double-blinded interventional trial to investigate the effect of oral magnesium supplementation on vascular calcification in subjects with chronic kidney disease. We hypothesize that oral magnesium supplementation will reduce vascular calcification in subjects with chronic kidney disease while not decreasing bone mineral density.

Conditions

Interventions

DIETARY_SUPPLEMENT

Mablet 360 mg

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Herlev Hospital

    collaborator OTHER

  • Nordsjaellands Hospital

    lead OTHER

Principal Investigators

  • Iain O Bressendorff, MD, PhD · Nordsjaellands Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2020-11-30
Completion
2021-07-31

Countries

  • Denmark
  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02542319 on ClinicalTrials.gov